JP2021529153A - 細胞透過性物質が融合したアプチド(aptide)が捕集された脂質ナノ粒子複合体及びその用途 - Google Patents
細胞透過性物質が融合したアプチド(aptide)が捕集された脂質ナノ粒子複合体及びその用途 Download PDFInfo
- Publication number
- JP2021529153A JP2021529153A JP2020537481A JP2020537481A JP2021529153A JP 2021529153 A JP2021529153 A JP 2021529153A JP 2020537481 A JP2020537481 A JP 2020537481A JP 2020537481 A JP2020537481 A JP 2020537481A JP 2021529153 A JP2021529153 A JP 2021529153A
- Authority
- JP
- Japan
- Prior art keywords
- glycero
- phosphocholine
- nanoparticle complex
- lipid nanoparticle
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nanotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
1,2-ジラウロイル-sn-グリセロ-3-ホスホコリン(1,2-dilauroyl-sn-glucero-3-phosphocholine, 12:0 PC, DLPC)、
1,2-ジトリデカノイル-sn-グリセロ-3-ホスホコリン(1,2-ditridecanoyl-sn-glycero-3-phophocholine, 13:0 PC)、
1,2-ジミリストイル-sn-グリセロ-3-ホスホコリン(1,2-dimyristoyl-sn-glycero-3-phosphocholine, 14:0 PC, DMPC)、
1,2-ジペンタデカノイル-sn-グリセロ-3-ホスホコリン(1,2-dipentadecanoyl-sn-glycero-3-phophocholine, 15:0 PC)、
1,2-ジパルミトイル-sn-グリセロ-3-ホスホコリン(1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 16:0 PC, DPPC)、
1,2-ジフィタノイル-sn-グリセロ-ホスホコリン(1,2-diphytanoyl-sn-glycero-3-phosphocholine, 4ME 16:0 PC)、
1,2-ジヘプタデカノイル-sn-グリセロ-3-ホスホコリン(1,2-dihentadecanoyl-sn-glycero-3-phophocholine, 17:0 PC)、
1,2-ジステアロイル-sn-グリセロ-3-ホスホコリン(1,2-distearoyl-sn-glycero-3-phosphocholine, 18:0 PC, DSPC)、
1,2-ジノナデカノイル-sn-グリセロ-3-ホスホコリン(1,2-dinonadecanoyl-sn-glycero-3-phophocholine, 19:0 PC)、
1,2-ジアラキドイル-sn-グリセロ-3-ホスホコリン(1,2-diarachidoyl-sn-glycero-phosphocholine, 20:0 PC)、
1,2-ジヘンアラキドイル-sn-グリセロ-3-ホスホコリン(1,2-dihenarachidoyl-sn-glycero-phosphocholine, 21:0 PC)、
1,2-ジベヘノイル-sn-グリセロ-3-ホスホコリン(1,2-dibehenoyl-sn-glycero-3-phosphocholine, 22:0 PC)、
1,2-ジトリコサノイル-sn-グリセロ-3-ホスホコリン(1,2-ditricosanoyl-sn-glycero-3-phosphocholine, 23:0 PC)、
1,2-ジリグノセロイル-sn-グリセロ-3-ホスホコリン(1,2-dilignoceroyl-sn-glycero-3-phosphocholine, 24:0 PC)、
1-パルミトイル-2-オレオイル-5,w-グリセロ-3-ホスホコリン(1-palmitoyl-2-oleoyl-5,w-glycero-3-phosphocholine, POPC)、
および1-パルミトイル-2-ステアロイル-5,w-グリセロ-3-ホスホコリン(1-palmitoyl-2-stearoyl-5,w-glycero-3-phosphocholine, PSPC)からなる群から選択されるいずれか一つ以上であり得る。一方、前記短鎖リン脂質は、
1,2-ジプロピオニル-sn-グリセロ-3-ホスホコリン(1,2-dipropionyl-sn-glycero-3-phosphocholine, 3:0 PC)、
1,2-ジブチリル-sn-グリセロ-3-ホスホコリン(1,2-dibutyryl-sn-glycero-3-phosphocholine, 4:0 PC)、
1,2-ジペンタノイル-sn-グリセロ-3-ホスホコリン(1,2-dipentanoyl-sn-glycero-3-phosphocholine, 5:0 PC)、
1,2-ジヘキサノイル-sn-グリセロ-3-ホスホコリン(1,2-dihexanoyl-sn-glycero-3-phosphocholine, 6:0 PC, DHPC)、
1,2-ジヘプタノイル-sn-グリセロ-3-ホスホコリン(1,2-diheptanoyl-sn-glycero-3-phosphocholine, 7:0 PC, DHPC)および
1,2-ジオクタノイル-sn-グリセロ-3-ホスホコリン(1,2-dioctanoyl-sn-glycero-3-phosphocholine, 8:0 PC)からなる群から選択されるいずれか一つ以上であり得る。
以下、本発明を下記の実施例により詳細に説明する。但し、下記の実施例は、本発明を例示するものであり、本発明がこれらによって制限されるものではない。
Claims (15)
- 細胞透過性物質が融合したアプチドが捕集された脂質ナノ粒子複合体。
- 前記脂質ナノ粒子複合体が、長鎖および短鎖リン脂質を含む、請求項1に記載の脂質ナノ粒子複合体。
- 前記長鎖および短鎖リン脂質が、0.5〜7:1のモル比で含まれる、請求項2に記載の脂質ナノ粒子複合体。
- 前記長鎖リン脂質が、
1,2-ジラウロイル-sn-グリセロ-3-ホスホコリン(1,2-dilauroyl-sn-glucero-3-phosphocholine, 12:0 PC, DLPC)、
1,2-ジトリデカノイル-sn-グリセロ-3-ホスホコリン(1,2-ditridecanoyl-sn-glycero-3-phophocholine, 13:0 PC)、
1,2-ジミリストイル-sn-グリセロ-3-ホスホコリン(1,2-dimyristoyl-sn-glycero-3-phosphocholine, 14:0 PC, DMPC)、
1,2-ジペンタデカノイル-sn-グリセロ-3-ホスホコリン(1,2-dipentadecanoyl-sn-glycero-3-phophocholine, 15:0 PC)、
1,2-ジパルミトイル-sn-グリセロ-3-ホスホコリン(1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 16:0 PC, DPPC)、
1,2-ジフィタノイル-sn-グリセロ-ホスホコリン(1,2-diphytanoyl-sn-glycero-3-phosphocholine, 4ME 16:0 PC)、
1,2-ジヘプタデカノイル-sn-グリセロ-3-ホスホコリン(1,2-dihentadecanoyl-sn-glycero-3-phophocholine, 17:0 PC)、
1,2-ジステアロイル-sn-グリセロ-3-ホスホコリン(1,2-distearoyl-sn-glycero-3-phosphocholine, 18:0 PC, DSPC)、
1,2-ジノナデカノイル-sn-グリセロ-3-ホスホコリン(1,2-dinonadecanoyl-sn-glycero-3-phophocholine, 19:0 PC)、
1,2-ジアラキドイル-sn-グリセロ-3-ホスホコリン(1,2-diarachidoyl-sn-glycero-phosphocholine, 20:0 PC)、
1,2-ジヘンアラキドイル-sn-グリセロ-3-ホスホコリン(1,2-dihenarachidoyl-sn-glycero-phosphocholine, 21:0 PC)、
1,2-ジベヘノイル-sn-グリセロ-3-ホスホコリン(1,2-dibehenoyl-sn-glycero-3-phosphocholine, 22:0 PC)、
1,2-ジトリコサノイル-sn-グリセロ-3-ホスホコリン(1,2-ditricosanoyl-sn-glycero-3-phosphocholine, 23:0 PC)、
1,2-ジリグノセロイル-sn-グリセロ-3-ホスホコリン(1,2-dilignoceroyl-sn-glycero-3-phosphocholine, 24:0 PC)、
1-パルミトイル-2-オレオイル-5,w-グリセロ-3-ホスホコリン(1-palmitoyl-2-oleoyl-5,w-glycero-3-phosphocholine, POPC)、および
1-パルミトイル-2-ステアロイル-5,w-グリセロ-3-ホスホコリン(1-palmitoyl-2-stearoyl-5,w-glycero-3-phosphocholine, PSPC)からなる群から選択されるいずれか一つ以上である、請求項2に記載の脂質ナノ粒子複合体。 - 前記短鎖リン脂質が、
1,2-ジプロピオニル-sn-グリセロ-3-ホスホコリン(1,2-dipropionyl-sn-glycero-3-phosphocholine, 3:0 PC)、
1,2-ジブチリル-sn-グリセロ-3-ホスホコリン(1,2-dibutyryl-sn-glycero-3-phosphocholine, 4:0 PC)、
1,2-ジペンタノイル-sn-グリセロ-3-ホスホコリン(1,2-dipentanoyl-sn-glycero-3-phosphocholine, 5:0 PC)、
1,2-ジヘキサノイル-sn-グリセロ-3-ホスホコリン(1,2-dihexanoyl-sn-glycero-3-phosphocholine, 6:0 PC, DHPC)、
1,2-ジヘプタノイル-sn-グリセロ-3-ホスホコリン(1,2-diheptanoyl-sn-glycero-3-phosphocholine, 7:0 PC, DHPC)および
1,2-ジオクタノイル-sn-グリセロ-3-ホスホコリン(1,2-dioctanoyl-sn-glycero-3-phosphocholine, 8:0 PC)からなる群から選択されるいずれか一つ以上である、請求項2に記載の脂質ナノ粒子複合体。 - 前記脂質ナノ粒子複合体が、円板形(discoid)である、請求項1に記載の脂質ナノ粒子複合体。
- 前記細胞透過性物質が、ペプチドおよび化合物からなる群から選択されるいずれか一つ以上である、請求項1に記載の脂質ナノ粒子複合体。
- 前記脂質ナノ粒子複合体が、10〜500nmの直径を有する、請求項1に記載の脂質ナノ粒子複合体。
- 細胞透過性物質が融合したアプチドが、脂質ナノ粒子複合体の総重量に対して0.2〜30重量%で含まれる、請求項1に記載の脂質ナノ粒子複合体。
- 前記脂質ナノ粒子複合体が、水溶液中でコロイド安定性(colloidal stability)が1時間以上維持される、請求項1に記載の脂質ナノ粒子複合体。
- 請求項1に記載の脂質ナノ粒子複合体を有効成分として含む炎症性皮膚疾患の予防または治療用薬学的組成物。
- 請求項1に記載の脂質ナノ粒子複合体を有効成分として含む炎症性皮膚疾患の予防または治療用皮膚外用剤。
- 請求項1に記載の脂質ナノ粒子複合体を有効成分として含む炎症性皮膚疾患の予防または改善用化粧料組成物。
- 請求項1に記載の脂質ナノ粒子複合体を有効成分として含む線維化の予防または治療用薬学的組成物。
- 請求項1に記載の脂質ナノ粒子複合体を有効成分として含む線維化の予防または改善用健康機能食品。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2019/006474 WO2020241925A1 (ko) | 2019-05-30 | 2019-05-30 | 세포투과성 물질이 융합된 앱타이드가 포집된 지질 나노 입자 복합체 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021529153A true JP2021529153A (ja) | 2021-10-28 |
JP7094582B2 JP7094582B2 (ja) | 2022-07-04 |
Family
ID=73550115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020537481A Active JP7094582B2 (ja) | 2019-05-30 | 2019-05-30 | 細胞透過性物質が融合したアプチド(aptide)が捕集された脂質ナノ粒子複合体及びその用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20200376138A1 (ja) |
JP (1) | JP7094582B2 (ja) |
WO (1) | WO2020241925A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113521306B (zh) * | 2021-07-28 | 2023-07-25 | 中国药科大学 | 具有透皮增强作用的传递体-外泌体膜融合制剂及其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009059425A1 (en) * | 2007-11-07 | 2009-05-14 | The University Of British Columbia | Stat3 inhibitors for the treatment of fibrosis |
KR102043248B1 (ko) * | 2018-02-20 | 2019-11-12 | 한국과학기술원 | 세포투과성 물질이 융합된 앱타이드가 포집된 지질 나노 입자 복합체 및 이의 용도 |
-
2019
- 2019-05-30 WO PCT/KR2019/006474 patent/WO2020241925A1/ko active Application Filing
- 2019-05-30 JP JP2020537481A patent/JP7094582B2/ja active Active
-
2020
- 2020-06-03 US US16/892,172 patent/US20200376138A1/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
ACS NANO, vol. 12, JPN6021048019, 2018, pages 6904 - 6916, ISSN: 0004657704 * |
ANGEW. CHEM. INT. ED., vol. 51, JPN6021048015, 2012, pages 1890 - 1894, ISSN: 0004657700 * |
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 8, JPN6021048017, 2013, pages 143 - 150, ISSN: 0004657701 * |
CANCER RESEARCH, vol. 74 (8), JPN6021048021, 2014, pages 2144 - 2151, ISSN: 0004657703 * |
JOURNAL OF MATERIALS CHEMISTRY B, vol. 1, JPN6021048022, 2013, pages 4723 - 4726, ISSN: 0004657702 * |
Also Published As
Publication number | Publication date |
---|---|
US20200376138A1 (en) | 2020-12-03 |
JP7094582B2 (ja) | 2022-07-04 |
WO2020241925A1 (ko) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meng et al. | Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity | |
US20210212948A1 (en) | Nanovesicles derived from cell membrane, and use thereof | |
KR20190128146A (ko) | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부염 개선 용도 | |
WO2016049867A1 (zh) | 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法 | |
JP6140120B2 (ja) | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 | |
US9815878B2 (en) | Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging | |
KR102045188B1 (ko) | 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부염 개선 용도 | |
Yang et al. | Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapy | |
Guo et al. | A CFH peptide-decorated liposomal oxymatrine inactivates cancer-associated fibroblasts of hepatocellular carcinoma through epithelial–mesenchymal transition reversion | |
Mi et al. | Asparagine endopeptidase-targeted ultrasound-responsive Nanobubbles alleviate tau cleavage and amyloid-β deposition in an Alzheimer's disease model | |
KR20190123709A (ko) | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부장벽 강화 내지 기능 개선 용도 | |
US10857199B2 (en) | Compounds and methods for increasing hair growth | |
KR102043248B1 (ko) | 세포투과성 물질이 융합된 앱타이드가 포집된 지질 나노 입자 복합체 및 이의 용도 | |
EP2994197B1 (en) | Pharmaceutical combination of an nsaid and atropine | |
JP7094582B2 (ja) | 細胞透過性物質が融合したアプチド(aptide)が捕集された脂質ナノ粒子複合体及びその用途 | |
Tian et al. | Co-delivery of bioactive peptides by nanoliposomes for promotion of hair growth | |
ES2715412T3 (es) | Péptido derivado de SOCS1 para su uso en complicaciones crónicas de la diabetes | |
US20210198631A1 (en) | Composition and method for preventing or treating eye disorder | |
KR102039302B1 (ko) | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부장벽 강화 내지 기능 개선 용도 | |
Qin et al. | Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy | |
US11931458B2 (en) | Exosome systems, products and methods | |
US9801848B2 (en) | Prevention of rosacea inflammation | |
TWI672147B (zh) | 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法 | |
US20210161816A1 (en) | Methods and compositions for treating skin afflictions | |
WO2012153616A1 (ja) | 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201028 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201028 |
|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20201028 Free format text: JAPANESE INTERMEDIATE CODE: A801 Effective date: 20200706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220304 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220615 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7094582 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |